{"id":"https://genegraph.clinicalgenome.org/r/77be6efc-f288-49b0-b1a2-e818f6b0615bv1.2","type":"EvidenceStrengthAssertion","dc:description":["*OTUD7A* is one of the genes within the recurrent 15q13.3 region. Individuals with heterozygous deletions of this region have phenotypes including intellectual disability, global developmental delays, autism spectrum disorder, and seizures (see the following dosage sensitivity curations for more information: [https://search.clinicalgenome.org/kb/gene-dosage/region/ISCA-46295](url), [https://search.clinicalgenome.org/kb/gene-dosage/region/ISCA-37411](url)). \n\nHeterozygous sequence variants in *OTUD7A* have been observed in individuals with autism spectrum disorder and schizophrenia (PMIDs: 29395074, 35931052). Because these phenotypes do not include epilepsy, the Epilepsy GCEP is not evaluating the gene-disease relationship for heterozygous OTUD7A sequence variants.\n\nBiallelic variants in *OTUD7A* were first reported in a patient with autosomal recessive complex neurodevelopmental disorder (MONDO:0100038) in 2020 (PMID: 31997314). This patient was found to have a homozygous p.Leu233Phe variant, and presented with global developmental delay, epilepsy, and hypotonia (PMID:29395074). The mechanism of pathogenicity is not clear at this time, but it has been suggested that the p.Leu233Phe variant results in loss of function (PMID:31997314). Later, another patient with a frameshift variant and the typical 15q13.3 deletion was reported with intellectual disability, epilepsy, global developmental delays, and dysmorphic features (PMID:33381903). This case has not been awarded points as part of our curation.\n\nIn summary, there is limited evidence to support the relationship between biallelic variants in *OTUD7A* and autosomal recessive complex neurodevelopmental disorder. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen Epilepsy Gene Curation Expert Panel on the meeting date June 6, 2023 (SOP Version 9).","*OTUD7A* is one of the genes within the recurrent 15q13.3 region. Individuals with heterozygous deletions of this region have phenotypes including intellectual disability, global developmental delays, autism spectrum disorder, and seizures (see the following dosage sensitivity curations for more information: [https://search.clinicalgenome.org/kb/gene-dosage/region/ISCA-46295](https://search.clinicalgenome.org/kb/gene-dosage/region/ISCA-46295), [https://search.clinicalgenome.org/kb/gene-dosage/region/ISCA-37411](https://search.clinicalgenome.org/kb/gene-dosage/region/ISCA-37411)). \n\nHeterozygous sequence variants in *OTUD7A* have been observed in individuals with autism spectrum disorder and schizophrenia (PMIDs: 29395074, 35931052). Because these phenotypes do not include epilepsy, the Epilepsy GCEP is not evaluating the gene-disease relationship for heterozygous OTUD7A sequence variants.\n\nBiallelic variants in *OTUD7A* were first reported in a patient with autosomal recessive complex neurodevelopmental disorder (MONDO:0100038) in 2020 (PMID: 31997314). This patient was found to have a homozygous p.Leu233Phe variant, and presented with global developmental delay, epilepsy, and hypotonia (PMID:29395074). The mechanism of pathogenicity is not clear at this time, but it has been suggested that the p.Leu233Phe variant results in loss of function (PMID:31997314). Later, another patient with a frameshift variant and the typical 15q13.3 deletion was reported with intellectual disability, epilepsy, global developmental delays, and dysmorphic features (PMID:33381903). This case has not been awarded points as part of our curation.\n\nIn summary, there is limited evidence to support the relationship between biallelic variants in *OTUD7A* and autosomal recessive complex neurodevelopmental disorder. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen Epilepsy Gene Curation Expert Panel on the meeting date June 6, 2023 (SOP Version 9)."],"dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/77be6efc-f288-49b0-b1a2-e818f6b0615b","GCISnapshot":"https://genegraph.clinicalgenome.org/r/7d6ba704-2333-4f70-9f74-54dfea711e5b","calculatedEvidenceStrength":"Limited","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/7d6ba704-2333-4f70-9f74-54dfea711e5b_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":["2023-06-06T19:00:00.000Z","2023-06-06T05:00:00.000Z"],"role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/7d6ba704-2333-4f70-9f74-54dfea711e5b_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2024-12-12T15:20:47.619Z","role":"Publisher"}],"curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7d6ba704-2333-4f70-9f74-54dfea711e5b_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5667d451-1a40-46cb-bba3-c2f9b0eedfd9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5667d451-1a40-46cb-bba3-c2f9b0eedfd9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31997314","rdfs:label":"Garret Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/9406460e-0005-425f-89ce-ebf03c6a05de","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001382637.1(OTUD7A):c.697C>T (p.Leu233Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA391892582"}},"detectionMethod":"Trio whole exome sequencing was performed and Sanger sequencing was used to confirm the presence of the variant.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0011344","obo:HP_0200134","obo:HP_0001252","obo:HP_0002463","obo:HP_0007270","obo:HP_0012469"],"previousTesting":true,"previousTestingDescription":"MRI: Normal (5 months)\nEEG:  typical pattern of infantile spasms with hypsarrythmia (14 months)\nMRI: VGB-associated reversible MRI signal change (1 yr)\nArray: 14q12 del (paternally inherited, ruled out due to presence of unrelated gene). \nMaternal: ACSL4 variants inherited (VOUS)","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/f3e8c5b7-d4c3-4086-98d0-abb91505fcf7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31997314","allele":{"id":"https://genegraph.clinicalgenome.org/r/9406460e-0005-425f-89ce-ebf03c6a05de"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/f3e8c5b7-d4c3-4086-98d0-abb91505fcf7","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f3e8c5b7-d4c3-4086-98d0-abb91505fcf7_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f3e8c5b7-d4c3-4086-98d0-abb91505fcf7_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In patient fibroblasts, steady-state expression levels of PA28-Î± and 20S proteasome subunits were impacted, presumably resulting in the measured decrease in proteasome activity.  Accumulation of proteins modified with K48-linked ubiquitin chains was also noted, linking OTUD7A disruption due to p.Leu233Phe with the observed disruption and impaired assembly of PA28-20S complexes.\n\nAnother study by Unda and colleagues (2023, PMID: 36604605) found a variety of functional and morphological impacts in p.Leu233Phe human induced pluripotent stem cell (iPSC)-derived induced glutamatergic neurons. This included impacts on dendritic arborization.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/2248acd6-bc4a-4ef2-95f1-e3cbbc17a7f4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2248acd6-bc4a-4ef2-95f1-e3cbbc17a7f4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33381903","rdfs:label":"Suzuki Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":14,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/67f9e000-2e63-445b-8362-7c92309d37da","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"GRCh37 15q13.2-15q13.3(chr15:30921917-32539666)x1"},{"id":"https://genegraph.clinicalgenome.org/r/5bde9342-0cf2-4f85-941d-7f812bb0cf62","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001382637.1(OTUD7A):c.1146del (p.Glu382AspfsTer11)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2580610992"}}],"detectionMethod":"Sanger sequencing was used to verify exome sequencing results. Chromosomal microarray was also performed after whole exome sequencing.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000494","obo:HP_0001263","obo:HP_0010804","obo:HP_0000400","obo:HP_0001252","obo:HP_0001250","obo:HP_0002650","obo:HP_0010864"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/df430d34-ed2e-40e3-b29d-9cba49128e63_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33381903","allele":{"id":"https://genegraph.clinicalgenome.org/r/5bde9342-0cf2-4f85-941d-7f812bb0cf62"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/9ad27ad9-f2bc-4fc4-ac29-16407e59648b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33381903","allele":{"id":"https://genegraph.clinicalgenome.org/r/67f9e000-2e63-445b-8362-7c92309d37da"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/df430d34-ed2e-40e3-b29d-9cba49128e63","type":"EvidenceLine","dc:description":"Downgrading to zero points because of the patient's 15q13.3 deletion.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/df430d34-ed2e-40e3-b29d-9cba49128e63_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/df430d34-ed2e-40e3-b29d-9cba49128e63_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"C. elegans knockout exhibited altered locomotion and smaller size realtive the wild type control. This is only one aspect of the broader neurodevelopmental phenotype, so this evidence has not been used to upgrade this variant's score.","functionalDataSupport":"No"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/9ad27ad9-f2bc-4fc4-ac29-16407e59648b","type":"EvidenceLine","dc:description":"Downgrading to zero points because this deletion spans multiple genes.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9ad27ad9-f2bc-4fc4-ac29-16407e59648b_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/7d6ba704-2333-4f70-9f74-54dfea711e5b_experimental_evidence_line","type":"EvidenceLine","specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0}],"evidenceStrength":"Limited","sequence":9511,"specifiedBy":"GeneValidityCriteria9","strengthScore":1,"subject":{"id":"https://genegraph.clinicalgenome.org/r/Eq--xDvB_qc","type":"GeneValidityProposition","disease":"obo:MONDO_0100038","gene":"hgnc:20718","modeOfInheritance":"obo:HP_0000007"},"version":"1.2","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_7d6ba704-2333-4f70-9f74-54dfea711e5b-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}